VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 330 filers reported holding VALEANT PHARMACEUTICALS INTL in Q2 2017. The put-call ratio across all filers is 1.24 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $732,000 | -29.4% | 66,400 | -7.0% | 0.04% | -39.1% |
| Q4 2016 | $1,037,000 | -38.4% | 71,400 | +4.1% | 0.07% | -34.9% |
| Q3 2016 | $1,684,000 | +26.5% | 68,600 | +3.8% | 0.11% | +7.1% |
| Q2 2016 | $1,331,000 | -40.8% | 66,100 | -22.7% | 0.10% | -47.3% |
| Q1 2016 | $2,249,000 | -73.6% | 85,500 | +2.2% | 0.19% | -70.9% |
| Q4 2015 | $8,508,000 | -57.6% | 83,700 | -25.6% | 0.64% | -60.4% |
| Q3 2015 | $20,068,000 | -52.3% | 112,500 | -40.6% | 1.63% | -46.9% |
| Q2 2015 | $42,042,000 | +36.6% | 189,250 | +22.1% | 3.07% | +6.6% |
| Q1 2015 | $30,786,000 | +240.1% | 155,000 | +145.1% | 2.88% | +172.0% |
| Q4 2014 | $9,052,000 | +23.2% | 63,250 | +12.9% | 1.06% | -6.9% |
| Q3 2014 | $7,347,000 | +5.4% | 56,000 | +1.4% | 1.14% | -9.0% |
| Q2 2014 | $6,968,000 | -0.3% | 55,250 | +4.2% | 1.25% | -22.5% |
| Q1 2014 | $6,987,000 | +26.6% | 53,000 | +12.8% | 1.61% | -18.2% |
| Q4 2013 | $5,518,000 | – | 47,000 | – | 1.97% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACCIPITER CAPITAL MANAGEMENT, LLC | 2,106,379 | $55,398,000 | 31.67% |
| Claren Road Asset Management, LLC | 80,000 | $2,820,000 | 24.27% |
| Okumus Fund Management Ltd. | 3,722,464 | $97,901,000 | 15.82% |
| Wingspan Investment Management, LP | 852,900 | $22,431,000 | 12.66% |
| FARLEY CAPITAL L.P. | 307,458 | $8,086,000 | 11.46% |
| Chou Associates Management | 976,843 | $25,725,000 | 8.35% |
| Wingspan Investment Management, LP | 550,700 | $14,483,000 | 8.17% |
| HAP Trading, LLC | 4,043,900 | $109,610,000 | 8.00% |
| LeVasseur Capital Partners LLC | 128,269 | $3,373,000 | 6.97% |
| Pershing Square Capital Management | 21,591,122 | $567,847,000 | 6.41% |